Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2015 Apr 28;112(9):1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9.

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.

Author information

1
Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.
2
1] Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA [2] Department of Surgery, University of California Los Angeles (UCLA), Los Angeles, CA, USA [3] Department of Medical and Molecular Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA [4] Jonsson Comprehensive Cancer Center (JCCC) at the University of California Los Angeles (UCLA), Los Angeles, CA, USA.

Abstract

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers of patients with melanoma, lung, kidney, bladder and triple-negative breast cancer, as well as in chemotherapy-refractory Hodgkin disease. There is already evidence from at least one randomised trial that anti-PD-1 therapy is superior to chemotherapy in the treatment of patients with metastatic melanoma, and two anti-PD-1 antibodies, pembrolizumab and nivolumab, have been approved by the US Food and Drug Administration for the treatment of patients previously treated for metastatic melanoma. It is anticipated that approvals by drug regulatory bodies will be forthcoming in several cancers in the next months.

PMID:
25856776
PMCID:
PMC4453674
DOI:
10.1038/bjc.2015.124
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center